Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

Alnylam Pharmaceuticals' (NASDAQ: ALNY) beardown momentum successful the archetypal 3 quarters of 2025 archetypal stalled, past evaporated. Many investors are nary uncertainty looking for a affirmative catalyst for the stock. They could get 1 soon.

Although Alnylam hasn't officially announced erstwhile it volition study fourth-quarter 2025 results, there's a bully accidental the Q4 update volition beryllium connected oregon astir Feb. 12, 2026. Should you bargain this biotech banal earlier then?

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

Wall Street looks for Alnylam's full Q4 gross to beryllium $1.16 billion. Analysts besides expect adjusted net per stock of $1.50.

Alnylam volition astir surely stock affirmative quality astir Amvuttra's commercialized traction successful its adjacent quarterly update. Sales for Amvuttra skyrocketed 162% twelvemonth implicit twelvemonth successful the 3rd 4th of 2025, driven by accelerated uptake successful the transthyretin cardiac amyloidosis (ATTR-CM) indication.

The company's full-year 2025 guidance projects combined income of Amvuttra and Onpattro of $2.5 cardinal astatine the midpoint of the range. Given that Onpattro's income are declining, it's tenable to expect each of the maturation successful Q4 volition travel from Amvuttra.

Don't look for important Amvuttra income successful planetary markets successful Q4, though. Alnylam's Chief Commercial Officer, Tolga Tanguler, said successful the Q3 net telephone that "the publication of ex-U.S. marketplace is going to stay comparatively modest, particularly for [the] 4th quarter." She added that stronger maturation volition apt beryllium seen successful Germany and Japan aboriginal successful 2026.

Also, the continued occurrence of Amvuttra has 1 insignificant drawback. As the income for the blockbuster cause increase, truthful bash the royalty rates paid to Alnylam's partners. As a result, the company's gross borderline volition astir apt decline.

Alnylam's absorption should besides supply updates connected its pipeline. Based connected comments during the company's third-quarter net call, Alnylam volition apt study the initiation of a Phase 3 survey evaluating nucresiran for the attraction of hereditary ATTR with polyneuropathy (hATTR-PN) and the initiation of a Phase 2 proceedings for mivelsiran successful Alzheimer's disease.

Alnylam continues to look similar an fantabulous semipermanent investment. Amvuttra has beardown momentum. The company's pipeline features respective promising candidates, including 3 programs successful late-stage testing. Alnylam besides expects to record to beforehand 3 to 4 caller therapies into objective investigating this year.